-
Kupcho seizes slim lead in US Women's Open at Riviera
-
Asian stocks take another hit from AI, Mideast worries
-
Game on: Trump set to attend game 3 of NBA Finals in New York
-
Nazi party records released online shatter German family myths
-
Political blows fly ahead of Trump's White House UFC fight
-
US allying itself with Colombian 'narco-traffickers,' Petro accuses
-
New York City's rules for AI in schools spark fury
-
Putin to confront weak economy at 'Russian Davos', under threat of Ukrainian drones
-
Australian far-right does U-turn on seizing foreigners' homes
-
Thousands protest in Albania against Kushner real estate project
-
Kiss confident Reds can 'scare' Chiefs in Super Rugby playoff
-
US imposes sanctions on Cuban president, Castro family members
-
Clark, Spaun part of four-way tie for lead at Memorial tournament
-
Trump confirms mass rally, scrapping US 250th concerts
-
Anthropic calls for pause of global AI development
-
Wemby counts on 'normal' Spurs to bounce back in NBA Finals
-
LA Olympics boss Wasserman says will not step down over Epstein links
-
Dangerous livestock pest case confirmed in Texas
-
Diallo gives Ivory Coast shock win over France
-
Latest 'Scary Movie' aims to cancel 'cancel culture,' creators say
-
Selfie-seeking fan banned for life by NBA after crashing Finals game
-
Lyles reigns in Rome 100m, Pathirage stuns with javelin
-
German serial killer found guilty of murder of French schoolboy
-
Trump announces $700 mn support for US coal projects
-
Dissing critics with humor, Hunter Biden finds social media stardom
-
SpaceX IPO: rockets, AI losses and Musk in control
-
In open letter to Putin, Zelensky calls for meeting and ceasefire
-
Four-wicket Robinson sparks New Zealand collapse in 1st Test after England slump
-
Pakistan upstage Australia for 2-1 ODI series win
-
Four-wicket Robinson rocks New Zealand in 1st Test after England collapse
-
Liverpool appoint Spaniard Iraola as new boss
-
Qualifier Chwalinska sets up Andreeva French Open final clash
-
Colombia court bans pro-Trump candidate from using jersey as symbol
-
Unfazed Antonelli plans to race with freedom
-
Four-wicket Robinson rocks New Zealand after England collapse in 1st Test
-
Designer Gabriela Hearst still believes in 'brilliance of humanity' despite AI
-
North Israel residents hold little hope for Lebanon truce deal
-
Qualifier Chwalinska downs Shnaider to reach French Open final
-
Robinson rocks New Zealand after England collapse in first Test
-
UN nuclear watchdog raises 'proliferation' fears over Iran sites
-
German prosecutors demand life term over Christmas market attack
-
Hamilton coy on Monaco chances
-
IMF boosting financial support for four African nations over war impact
-
'In the queue': Busy with Iran, US has little energy for Kyiv
-
Richard Gere says 'ashamed' of US migration policy
-
Romanian president nominates EU deputy Tomac as PM to end deadlock
-
Leclerc rejected rival offers to stick with Ferrari
-
What we know about Trump relatives' project in Albania
-
German prosecutors demand life term for Christmas market attack
-
Oil drops, stocks mostly higher despite AI concerns
Trump signs order to fast-track research on psychedelic drugs
US President Donald Trump on Saturday announced an easing of restrictions on research into psychedelic drugs -- such as so-called "magic mushrooms" -- that have shown promise in treating people with mental health conditions.
Flanked by US Health Secretary Robert F. Kennedy Jr, top medical officials and podcaster Joe Rogan, who has pushed for access to the drugs, Trump signed an executive order that would help federal researchers cut through the red tape to allow for quicker studies.
The president said the order would "clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA (Food and Drug Administration) and the Department of Veterans Affairs and facilitate fast rescheduling of any psychedelic drugs that become FDA approved."
Currently, many psychedelics including LSD and psilocybin ("magic mushrooms") are classified -- or "scheduled" -- as having high abuse and addiction potential, and are not approved for medical use, limiting the ability for scientists to study them.
If the FDA, which is charged with regulating pharmaceuticals in the United States, officially finds a medical benefit for some of the psychedelics, they could be rescheduled, allowing for greater clinical use.
The order only provides for accelerated research and does not immediately require law enforcement authorities to reclassify the drugs, meaning therapeutic use will not expand immediately.
In recent years, there has been a growing push to research the effects of the drugs in treating people -- especially war veterans -- with difficult anxiety and depression cases, especially those who had experienced traumatic stress.
Many veterans and other patients have complained that traditional antidepressant cocktails not only fail to work but change their personalities in ways that alienate them from their friends and family.
In 2023, 6,398 veterans took their own lives, the Department of Veterans Affairs said.
During the signing ceremony at the White House, Trump pointed to one drug called ibogaine, claiming patients who had taken it "experienced an 80 to 90 percent reduction in symptoms of depression and anxiety within one month."
"Can I have some, please?" he joked.
The full extent of the benefits and potential side effects of psychedelic medications is not yet known, since research has been restricted.
While many are thought to show promising mental health benefits, there are risks. Ibogaine, for instance, is thought to potentially damage the heart.
If you are a US veteran in need of help, or concerned about one, you can dial 988 and press 1, or visit www.veteranscrisisline.net.
I.Stoeckli--VB